Shire PLC (SHPG) Receives Overweight Rating from JPMorgan Chase & Co.
Several other brokerages have also weighed in on SHPG. Zacks Investment Research raised shares of Shire PLC from a sell rating to a hold rating in a research report on Thursday, August 4th. Citigroup Inc. reiterated a buy rating on shares of Shire PLC in a report on Tuesday, September 27th. Jefferies Group reiterated a buy rating and set a $262.00 price target on shares of Shire PLC in a report on Wednesday, September 7th. BTIG Research reiterated a buy rating and set a $230.00 price target on shares of Shire PLC in a report on Tuesday, July 12th. Finally, Leerink Swann reiterated a buy rating and set a $213.00 price target on shares of Shire PLC in a report on Tuesday, July 12th. Five research analysts have rated the stock with a hold rating and twenty-two have issued a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus target price of $232.75.
Shares of Shire PLC (NASDAQ:SHPG) opened at 197.705 on Monday. Shire PLC has a one year low of $147.60 and a one year high of $231.32. The firm’s 50 day moving average is $196.04 and its 200-day moving average is $186.49. The firm has a market capitalization of $58.89 billion, a PE ratio of 41.086 and a beta of 1.16.
Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 earnings per share for the quarter, beating the consensus estimate of $3.03 by $0.35. The firm had revenue of $2.43 million for the quarter, compared to analyst estimates of $2.28 billion. Shire PLC had a net margin of 13.19% and a return on equity of 17.70%. The company’s revenue for the quarter was up 55.9% on a year-over-year basis. During the same quarter last year, the firm earned $2.63 earnings per share. On average, equities research analysts predict that Shire PLC will post $12.92 earnings per share for the current fiscal year.
The business also recently disclosed a dividend, which will be paid on Friday, October 7th. Stockholders of record on Friday, September 9th will be paid a dividend of $0.139 per share. The ex-dividend date of this dividend is Wednesday, September 7th. Shire PLC’s dividend payout ratio is currently 15.63%.
Several large investors have recently made changes to their positions in SHPG. Quadrant Capital Group LLC boosted its stake in shares of Shire PLC by 157.6% in the second quarter. Quadrant Capital Group LLC now owns 608 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 372 shares in the last quarter. Canal Insurance CO bought a new stake in shares of Shire PLC during the second quarter worth about $102,000. FTB Advisors Inc. boosted its stake in shares of Shire PLC by 3.1% in the second quarter. FTB Advisors Inc. now owns 600 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 18 shares in the last quarter. Duncker Streett & Co. Inc. bought a new stake in shares of Shire PLC during the second quarter worth about $111,000. Finally, Ropes Wealth Advisors LLC bought a new stake in shares of Shire PLC during the second quarter worth about $114,000. Institutional investors own 24.26% of the company’s stock.
Shire PLC Company Profile
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.